Share This Author
Genomic analyses identify molecular subtypes of pancreatic cancer
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S…
Biological determinants of endocrine resistance in breast cancer
The development of large-scale computational and genetic approaches offers the promise of identifying the mediators of endocrine resistance that may be exploited as potential therapeutic targets and biomarkers of response in the clinic.
Cyclin D as a therapeutic target in cancer
- E. Musgrove, C. Caldon, J. Barraclough, A. Stone, R. Sutherland
- Biology, ChemistryNature Reviews. Cancer
- 1 August 2011
The ability of cyclin D1 to activate the cyclin-dependent kinases CDK4 and CDK6 is the most extensively documented mechanism for their oncogenic actions and provides an attractive therapeutic target.
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
It is found that frequent and diverse somatic aberrations in genes described traditionally as embryonic regulators of axon guidance, particularly SLIT/ROBO signalling, are also evident in murine Sleeping Beauty transposon-mediated somatic mutagenesis models of pancreatic cancer, providing further supportive evidence for the potential involvement ofAxon guidance genes in pancreatic carcinogenesis.
Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer.
It is concluded that, by binding to a subset of EREs, the AR can prevent activation of target genes that mediate the stimulatory effects of 17beta-estradiol on breast cancer cells.
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers
- C. Fedele, L. Ooms, C. Mitchell
- Biology, MedicineProceedings of the National Academy of Sciences
- 2 December 2010
Evidence is provided that INPP4B functions as a tumor suppressor by negatively regulating normal and malignant mammary epithelial cell proliferation through regulation of the PI3K/Akt signaling pathway, and that loss of IN PP4B protein is a marker of aggressive basal-like breast carcinomas.
Estrogen-induced Activation of Cdk4 and Cdk2 during G1-S Phase Progression Is Accompanied by Increased Cyclin D1 Expression and Decreased Cyclin-dependent Kinase Inhibitor Association with Cyclin…
- O. Prall, B. Sarcevic, E. Musgrove, C. K. Watts, R. Sutherland
- Biology, ChemistryJournal of Biological Chemistry
- 18 April 1997
The treatment of MCF-7 breast cancer cells with the pure estrogen antagonist ICI 182780 is treated to inhibit estrogen-induced gene expression and induce G1 phase arrest to provide an explanation for the early activation of both cyclin D1-Cdk4 and cyclin E-C DK2 complexes that accompany G1-S phase progression in response to estradiol.
International network of cancer genome projects
Systematic studies of more than 25,000 cancer genomes will reveal the repertoire of oncogenic mutations, uncover traces of the mutagenic influences, define clinically relevant subtypes for prognosis and therapeutic management, and enable the development of new cancer therapies.
Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
- E. Millar, P. Graham, R. Sutherland
- MedicineJournal of clinical oncology : official journal…
- 1 October 2009
Although this approach provides additional information to predict time to IBTR, LRR, DDFS, and death from breast cancer, its predictive power is less than that of traditional pathologic indices.
Progestin regulation of cellular proliferation.
Recent studies on breast cancer cells and immature rat uterus support the view that some of the largest physiological changes in rates of growth and cell proliferation are mediated by steroid hormones.